reSee.it - Related Video Feed

We received four Pfizer vaccines, and the one we sequenced is different from any previously analyzed. This may be an earlier version that Pfizer modified later. The vaccine contains a common plasmid used in coronavirus research, which raises questions about its origin. While Pfizer is the likely source, it's possible it leaked from a lab. We found similarities and differences in the components of the vaccines. The contamination hypothesis is unlikely since the plasmids have never been handled in our labs, and formalin fixation prevents spike protein production. Pfizer could have multiple undisclosed plasmids, which would be concerning, especially since we found one in a colon cancer sample that produces spike protein at high levels, indicating it could be replication competent and potentially transmissible. Transmissible cancer is a significant issue.

Quan et al demonstrated that the introduction of DNA into a cell, even without integration, can trigger the oncogenic cGAS-STING pathway. The speaker claims that the presence of an SV40 origin of replication, a mammalian origin, in a vaccine grown in E. coli is reckless because it allows the plasmid DNA to replicate episomally in the host. The speaker alleges evidence suggests Pfizer, unlike Moderna, may have included this origin of replication due to carelessness. The speaker highlights concerns about nucleic acid persistence, noting that RT-PCR methods used in studies like Krausson and Rolchen may have amplified both DNA and RNA. The speaker suggests that prior studies assumed detected nucleic acids were RNA, but that further investigation using primers specific to the plasmid backbone might reveal the presence of residual plasmid DNA. The Krausson paper found nucleic acids present for thirty days in heart tissues, and the Rolchen paper found them for sixty days.

Moderna holds a patent for using RNA in vaccines, acknowledging that RNA is superior to DNA due to concerns about DNA-related problems like insertional immunogenesis and genotoxicity. The FDA claims to be unaware of any issues, but Moderna's own patent raises the same concerns about DNA. It appears that DNA is present in the RNA preparation as a contaminant, as it is used in the process of making RNA. Recent findings by scientists revealed large numbers of DNA fragments in the RNA preparation, including sequences that are not normally allowed in human use, such as an antibiotic resistance gene and sequences from simian virus 40. These DNA fragments can potentially lead to DNA damage, birth defects, and cancer.

Speaker 0: I read the sequence and it's high-resolution. Speaker 1: It may seem low at first, but it's understandable. Speaker 0: This is written in a loop. Speaker 1: This is the genetic sequence of the spike protein. The issue is that the model RNA has a sequence that surprised me. We need to design it a bit. It contains part of the sequence SB4T, which is necessary for gene expression. The problem is that it is found in a virus that has negative effects. Also, there is another problem with this sequence. The DNA that has been transferred so far becomes more susceptible to mutation. It's a problematic point. Speaker 1: So, this SB4T sequence is also included in the promoter of this SB method, which allows it to migrate to the nucleus. Speaker 0: This is quite famous. Speaker 1: Yes, it is. The issue is that it has no relation to the process of synthesizing the messenger RNA. Speaker 0: Why did they keep the promoter sequence in the SB4T that has nothing to do with the camera's perspective in the messenger RNA synthesis process?

The symposium revolves around the science and safety implications of Replicating/Replicon vaccines and broader RNA vaccine platforms, with a sequence of expert presentations and reactions from the panel. -荒川博 presents the central premise that Replicon vaccines (replicating or self-amplifying RNA vaccines) raise unique safety and biosafety concerns beyond traditional mRNA vaccines. He frames the discussion around the idea that these vaccines “increase and mutate” within the host, potentially evolving in ways that could affect humans and populations. He references specific real-world events and case observations, including severe vascular events and tissue damage in some vaccine recipients, as motivation to scrutinize this technology carefully. -荒川 emphasizes that Replicon vaccines differ from conventional mRNA vaccines by embedding replicative machinery so that the RNA self-amplifies inside cells. He explains that, unlike ordinary mRNA vaccines, replication can produce more copies of the RNA and additional viral proteins, potentially leading to unexpected immune and biological consequences. He notes that the Alpha virus replicase used in some designs is designed to enable replication and increased antigen production, but that high mutation and recombination potential could yield variants or new properties. -藤本、藤田（参加者は複数） and others discuss the science of replication in viruses, highlighting the Central Dogma nuances. They describe that normally DNA → RNA → protein is the standard flow, but some viruses (RNA viruses and certain retroviruses) can reverse or bypass parts of this flow (RNA to DNA in retroviruses; RNA to RNA replication in some RNA viruses). This provides a conceptual basis for why replicating vaccines could, in principle, generate abnormal replication dynamics or new variants. -コロナウイルスRNAワクチンの議論では、Repliconの増殖と変異率の高さ、組換えの可能性、体内拡散の可能性を挙げて、「増えると変わる」性質が人の体内でどう影響するかが核心テーマとして挙げられます。アルファウイルス由来のレプリカーゼを使う場合、修復機能が不完全なRNAの増殖過程で、予想外の抗原変異を引き起こすリスクがあるとの指摘が出てきます。 -リスクの具体例として、ウイルスの殻（エンベロープ）とエクソソームを介した分布、自己拡散型ワクチンによる体内の遺伝子素材の取り込み、さらには他の人へ感染・伝播するアウトブレークの可能性、という仮説的懸念が提示されます。レプリコンワクチンは「空の遺伝子を抗原遺伝子に置き換えた陰性空間を持つウイルス」という説明が繰り返され、組換え・遺伝子交換・逆転など、従来のDNA・RNA動態の外に出る事象が起こり得ると議論されます。 -一部のスピーカーは、日本での試験・臨床・規制の動きを取り上げ、FDA/国内基準値を超えるDNA混入、SV40プロモーター混入の報告など、製品レベルでの懸念を指摘します。ケビン・マッカーシー氏の分析紹介では、日本市場で使われているファイザー社のコロナワクチンにDNA混入の痕跡があったこと、SV40プロモーター混入の可能性が指摘され、脂質ナノ粒子を通じた細胞内へのDNA／エクソンの取り込みリスクが懸念事項として挙げられます。これにより、RNAワクチンのフォーマットが終わるのではなく、プラットフォーム自体が拡大・進化する過程で新たなリスクを生む可能性を示唆します。 -IGG4関連疾患の急増とコロナワクチンの関連を例示する報告を紹介。IGG-4抗体が高値となり、多様な臓器炎症を引き起こす病態が観察され、ウイルス感染・ワクチン接種と免疫抑制・過剰免疫の連携が臨床で見られるケースの存在が議論されました。これにより、免疫の過剰反応・異常免疫を招く可能性があるとの懸念が示唆されました。 -ウイルス学・免疫学の専門家は、Repliconワクチンの「増殖・変異・組換えの三拍子」が、長期的・広範な公衆衛生影響をもたらし得る点を強調します。従来のウイルスワクチンの枠組みを超え、自己拡散・他者伝播・遺伝子汚染の可能性を定量的に評価する必要があると主張します。 -議論は、Repliconの潜在的リスクと実利を天秤にかけるもので、現時点で「安全」と断定できないという結論に至る場面が多くありました。実臨床での結果を長期観察で検証し、エビデンスに基づく判断を求める声が複数の speaker から出ました。 -最後に、メディア・一般市民への啓蒙の喚起と、透明性の高い情報提供、そして次世代ワクチン開発の安全性を担保するための厳格な規制・評価の重要性が強調されました。現状の科学的理解には限界があり、今後も公衆衛生への影響を見据えた厳密な検証が不可欠であるとの結論が共有されました。 overall, the event centers on the scientific basis, potential risks, and regulatory considerations of Replicon vaccines, contrasted with traditional mRNA vaccines, with emphasis on mutation, recombination, potential horizontal spread, DNA contamination concerns, immune dysregulation (including IGG4-associated phenomena), and the need for rigorous, transparent evaluation before broad deployment.

The presence of DNA plasmids and undisclosed proteins in the Pfizer COVID-19 vaccine has raised concerns. The DNA plasmids, originating from E. Coli, were not properly removed during manufacturing, resulting in contamination. Additionally, two proteins from the simian virus 40 (SV40) were found in the vaccine, which is associated with certain cancers. SV40 was present in polio vaccines administered to millions of Americans in the past. Injecting these proteins and DNA into the body can potentially lead to mutations and increased risk of cancer. This discovery suggests a higher chance of mutation from the Pfizer COVID-19 vaccine.

Moderna holds a patent for using RNA in vaccines, acknowledging that RNA is better than DNA due to concerns about DNA-related problems like insertional immunogenesis and genotoxicity. The FDA claims to be unaware of these concerns, but Moderna's own patent highlights them. The presence of DNA in the vaccines is considered a contaminant, as it is used in the process of making RNA. Recent findings by scientists in the US and Canada revealed large amounts of DNA fragments in the RNA preparation, including sequences not allowed for human use, such as an antibiotic resistance gene and sequences from simian virus 40. These DNA fragments pose risks of DNA damage, including birth defects and cancer.

When COVID-19 vaccines were sequenced, commercial annotation software highlighted functional parts of the plasmids, including antibiotic resistance genes and SV40 components. The speaker claims that Pfizer had to manually remove these annotations before submitting the plasmid map to regulators. According to the speaker, regulators received the DNA sequence, but the sponsor is obligated to annotate every open reading frame and promoter, even if their function is unknown. The speaker alleges that Pfizer intentionally removed annotations, hiding them from the FDA, which the speaker believes is a violation of guidelines. The speaker suggests the reason for hiding SV40 components is due to SV40 virus contamination in polio vaccines and its debated link to cancer. The speaker asserts that while epidemiological data is confounded by vaccine shedding, laboratory studies show SV40 is a potent oncogenic virus. The speaker claims that the vaccines contain some of the more carcinogenic components of that virus, and that these sequences are functional and have consequences.

Kevin McKernan, an experienced genomic expert, discusses his findings regarding mRNA vaccines. He discovered that the expression vectors for the vaccines, which are used to produce the spike protein, are still present in the vials. These vectors exceed the guidelines set by the EMA and FDA. McKernan explains the two different processes used in the clinical trials and how residual plasmids from E. coli amplification remain in the vaccines. He specifically highlights the presence of the SV40 promoter in Pfizer vaccines, which was not disclosed to the regulatory agencies. McKernan's team conducted quantitative PCR assays and found high levels of vector DNA in the vials. He emphasizes the importance of understanding the potential risks associated with this contamination and encourages others to replicate his work.

The Pfizer vaccine may contain DNA in addition to mRNA, according to a scientist who sequenced the vaccine in their lab. The DNA is a vector used in the production of the mRNA. The scientist examined vials of the vaccine from a local vaccination program and found DNA in them. This DNA could potentially be linked to rare but serious side effects, such as death from cardiac arrest. It has the ability to integrate into the genomic DNA of cells, potentially causing long-term effects. The presence of this DNA raises concerns about the regulatory process that allowed it to be included in the vaccine. There is a theoretical risk of autoimmune reactions and future cancer development. Further investigation is needed to determine the extent of these risks.

In this video, the speakers discuss the omission of the SV40 promoter sequence in the plasmid used in vaccines. They highlight that the plasmid was annotated with various details except for the SV40 region, which is active in a million cells. Health Canada stated that sponsors should identify any biologically functional DNA, such as the SV40 enhancer, during submission. However, Pfizer did not specifically identify the SV40 sequence. The speakers explain that the plasmid map provided by Pfizer did not include annotations for the SV40 region or the F1 origin. They speculate that this omission was intentional and not a simple oversight. The speakers also mention the use of SnapGene software for plasmid annotation.

The DNA sequence in gene therapy plasmids contains the SV40 promoter and enhancer region, an SV40 origin of replication, and an SV40 poly A signal. The SV40 enhancers are nuclear targeting sequences, ensuring the DNA enters the cell nucleus, especially during cell division when the nuclear envelope dissolves. Claims that it doesn't reach the nucleus are misleading. This plasmid was sourced from Pfizer's gene therapy department. The SV40 promoter and enhancer bind to the p53 gene, a tumor suppressor, which is concerning given that the spike protein also inhibits p53 expression. Literature indicates this sequence is a hypermutability element, inducing mutations in nearby DNA, suggesting potential tumorigenic activity. These findings contradict claims that this DNA has no function.

Key points: "the vials that were in fact approved are not the vials that were given to the public." The clinical trial used "process one that used PCR to make the DNA that was going to then turn into the RNA to make the spike protein." After the trial, "they switched" to a production process that "manufactured this DNA in E. Coli," introducing endotoxin risk. "There are these plasmids that have additional DNA that were not present in the actual clinical trial." Sequencing found mixtures, including "expired" and samples that had "been tapped into." Regarding Pfizer, "the Pfizer vaccines actually had a component that was not disclosed to the regulators." "The plasmid map on the right is what was disclosed to the EMA" with "no mention of the SV40 components" now "inside this DNA sequence." "The plasma on the left is what we actually found," with components not disclosed to regulators nor to patients. Monovalent Pfizer; prior ones were the bivalent vaccines from Moderna and Pfizer.

Speaker 0: They argue that because the vaccine is classified as such, they don’t have to worry about being sued. They claim immunity from liability is dependent on there being no fraud, and there clearly was fraud. Speaker 1: They say there is fraud. They note that immunity from liability depends on fraud, and in light of that, it matters. They explain that there was fraud. Speaker 0: Expresses surprise and asks for caveats about fraud. Acknowledges there were caveats. Speaker 1: Confirms there is fraud and says it makes the situation more interesting. Speaker 0: Asks how fraud is defined, noting that drugs were sold with multiple studies and only one was good. Speaker 1: Responds with a point about safety testing for the mRNA vaccines. States that the insufficient safety testing was done before release, and that the product injected into billions of people involved DNA plasmids. There is massive contamination in the shots actually delivered, including the SV40 promoter from simian virus 40. The point is that safety testing for one drug was completed, but people were injected with something different that had other components that were not tested, which is described as fraudulent. Speaker 0: Requests an explanation of the SV40 issue for the audience. Speaker 1: Describes production techniques used to generate the product. Explains that a plasmid, a circular piece of DNA, was used to produce the product in vats, with bacteria performing the production, later coated in lipid nanoparticle. There is a requirement to purify DNA and set standards for DNA contamination, with limits that cannot be exceeded. In this case, the problem isn’t only poor quality control but that there was a more painstaking way to produce the same product that did not involve DNA plasmids at all. Consequently, leftover material in vials injected into people contained DNA contamination across the board. Kevin McKernan tested vials, finding DNA contamination in the samples. Speaker 1: Explains that the DNA left over includes the SV40 promoter, a genetic trigger from simian virus 40, which is known to be carcinogenic. Since this promoter is left in the vials from injections given to people, it challenges the claim that the mRNA shots could not integrate into the genome. While acknowledging that there are cellular processes such as reverse transcription, the speaker asserts that even the claim of “no DNA” is false because there is DNA in the vials, specifically DNA with the SV40 promoter, a genetic engineering tool with carcinogenic potential. The speaker concludes that this appears to be fraud: injecting a different product into the public on the basis of safety testing that was conducted with a product produced by a different process. Speaker 0: Reiterates the conclusion: you can’t inject a different product into the public on the basis of safety testing that was done with something produced by a different process.

A colon biopsy from a Pfizer-vaccinated individual who died a month after tumor emergence revealed SV40 in the origin of replication from the Pfizer vaccine. Preliminary sequencing suggests the presence of Pfizer's vaccine. The vaccine DNA copy number was greater than the human genome, indicating replication. PCR signals suggest the vaccine concentration is similar to or higher than the original vial, despite dilution in the body. This indicates the mammalian origin of replication in Pfizer's vaccine is active in human tumors. This finding may explain shedding, which is not supposed to occur because the COVID vaccine is not intended to alter DNA. However, evidence suggests that the vaccine may be altering DNA, making it a VGBT (genome altering) product. This could mean that spike proteins are continually created, and shedding is real.

Health Canada initially claimed the Pfizer vaccine did not contain SV40, but later acknowledged its presence, stating it has no functional role. Despite this, they sought clarification from Pfizer about the residual fragments. When asked for information, Health Canada provided redacted documents, raising questions about transparency. A technique called fluorometry, which labels DNA with fluorescent markers, revealed that some RNA vaccines, particularly Moderna's, could contain up to 10 trillion copies of DNA fragments per dose. This is concerning because just 3 to 10 copies can facilitate the incorporation of SV40 DNA into a cell's nuclear genome, potentially leading to mutations associated with cancer.

A peer-reviewed paper confirms Pfizer's mRNA vaccine is contaminated with DNA and SV40 enhancers, considered dangerous. Pfizer used bacterial plasma DNA during mass production, leading to contamination with spike protein genes, antibiotic resistance markers, and SV40 enhancers. Researchers found 4-5 times more DNA than the safe limit. The DNA fragments could integrate into the human genome due to the SV40 enhancer. Injected vaccine samples caused super strong kidney cells to produce spike protein, excreted via exosomes, potentially spreading body-wide. The vaccines were toxic to these cells, causing pathological changes. The DNA, tucked into lipid nanoparticles, could integrate into the human genome, turning the jab into accidental gene therapy. The SV40 enhancer drags DNA into the nucleus. The study suggests the inclusion of SV40 enhancers was deliberate, not accidental, and scrubbed from regulatory paperwork. Experts theorize this contamination could be linked to an explosion of turbo cancers. The study concludes mRNA shots should be suspended until safety is determined. Another study found vaccine spike protein expressed in cerebral arteries of stroke patients for up to 17 months, accompanied by an autoimmune response.

A peer-reviewed paper confirms Pfizer's mRNA vaccine is contaminated with dangerous DNA and SV40 enhancers. During production, bacterial plasmid DNA led to contamination with spike protein genes, antibiotic resistance markers, and SV40 enhancers. Researchers found four to five times more DNA than the safe limit; these DNA fragments could integrate into the human genome due to the SV40 enhancer. Experiments showed the vaccines were toxic to cells, causing pathological changes and spike protein production, potentially spreading body-wide via exosomes. The DNA contamination, tucked into lipid nanoparticles, could lead to unintended gene therapy. The SV40 enhancer, deliberately added but removed from regulatory paperwork, raises questions about Pfizer's intentions. Experts theorize this contamination could be linked to an increase in "turbo cancers," coinciding with Pfizer's acquisition of a cancer drugmaker. An epidemiologist noted the study found DNA from the manufacturing process way over regulatory limits, including the cancer-promoting SV40 promoter enhancer and spike-producing DNA. A separate study found vaccine spike protein expressed in cerebral arteries of stroke patients for up to seventeen months, potentially contributing to autoimmune responses. There are now 11 independent reports that have found, DNA contamination within these shots of up to 60000% above regulatory limits.

Moderna has a patent on the use of RNA for vaccines (patent number 2019-024-0317-A1). In that patent, Moderna explicitly acknowledges that RNA is superior to DNA for vaccine purposes because of “problems” including the possibility of insertional immunogenesis, which could lead to the activation of oncogenes or the integration of tumor suppressor genes. The transcript says that while the FDA says it is not aware of any concerns, Moderna’s own patent lays out the same concerns about DNA and insertional immunogenesis and genotoxicity, and that Moderna “knows it.” The discussion then turns to DNA as a contaminant. The transcript says DNA is left in because, in “process two,” circular DNA is purified from bacteria to make RNA; RNA makes protein; then the DNA is degraded and must be purified away from the RNA. It says the process is apparently not very good, and that DNA fragments were detected after some scientists in the U.S. and Canada obtained unopened vials with clear chain of custody, sampled them, and performed deep sequencing to reconstruct what circular plasmid DNA looked like in the RNA preparation. The transcript claims that these DNA fragments were not disclosed to the public. It adds that the reconstructed sequences include sequences “normally not allowed” in anything going into humans, including an antibiotic resistance gene for kanamycin or neomycin. It also says sequences from simian virus 40 (SV40) are present, specifically highly active promoter sequences. The transcript states that FDA older regulations said these must be avoided because they confer additional risk for insertional mutagenesis. The transcript further claims that when Pfizer provided documents to the FDA, EMA, and Health Canada, Pfizer took standard plasmid maps generated by publicly accessible programs and deleted the notation indicating SV40 sequences. It then says that the FDA did not reconstruct raw DNA sequences to check these maps and instead relied on Pfizer’s submissions. The transcript attributes the emergence of these findings to researchers performing work “akin to the lot release testing that is not happening.” When asked about downstream bad outcomes, the transcript says the outcomes associated with DNA damage include birth defects and cancer.

The Pfizer vaccine contains not only mRNA but also plasma DNA from the vector used in its production. I sequenced samples from two batches of the vaccine in Colombia and found this DNA, which raises concerns about potential health risks. This DNA could integrate into the genomic DNA of cells, leading to permanent changes. Such integration poses theoretical risks, including autoimmune responses and cancer, depending on where the DNA inserts itself in the genome. While these risks may be rare, they warrant investigation to understand their implications better.

The panel discusses replication (replicon) vaccines and their potential dangers, focusing on how they differ from conventional messenger RNA (mRNA) vaccines and what new risks might emerge as this technology develops. Key points and concerns raised - Replicon vaccines concept and fundamental differences - Replicon vaccines use replication-capable genetic material, so the embedded genetic information not only makes antigen proteins but also multiplies inside the cell. They are described as having both constitutive function (the ability to make proteins) and, crucially, the capacity to replicate, which distinguishes them from traditional, non-replicating mRNA vaccines. - It is explained that replication introduces additional mutation and recombination opportunities, because the RNA genome is copied more than once, and the process can produce variants that differ from the original design. - Central dogma exceptions and viral biology - The speakers explain that while the central dogma (DNA → RNA → protein) generally governs biology, some viruses violate this, with RNA viruses that replicate via RNA-dependent replication and even some reverse-transcribing retroviruses that convert RNA to DNA and integrate into genomes. This context is used to frame why replicon vaccines could behave unpredictably. - Potential risks of replication and spread - A core concern is that the replicon approach might allow the vaccine genome to spread beyond the initial target cells, potentially reaching other cells and tissues, or even spreading to other people via exosomes or other means. Exosomes can transport DNA, RNA, and proteins between cells; thus, the replicon genome could in theory be disseminated. - The possibility of homologous or heterologous recombination between replicon genomes and wild-type viruses could yield new variants. The panel emphasizes the difficulty of controlling such recombination in a living system. - Specific material and design considerations - The use of viral components like spike protein genes in replicon vaccines raises concerns about how these proteins might mutate or recombine during replication, potentially altering antigen presentation or safety. - A concern is raised about the lack of repair mechanisms in RNA replication (as opposed to DNA replication), which could make error rates higher and lead to unpredictable changes. - The panel notes that current replicon vaccine designs (including those using alphavirus backbones) inherently carry high mutation and recombination risk, and that the replicating systems may encounter unpredictable evolutionary dynamics inside the human body. - Safety signals and clinical anecdotes - The speakers cite cases of adverse events temporally associated with vaccines, including vascular inflammation and thrombosis, stroke-like events, and myocarditis, to illustrate that immune responses to vaccines can be complex and occasionally severe. They emphasize that such observations do not establish causality, but argue they warrant careful scrutiny. - There are references to cases of acute vascular and neural complications following repeated vaccination, and to broader immune dysregulation phenomena, including IGG4-related disease and immune dysregulation syndromes that can involve multiple organs. - One example concerns a patient who developed sudden limb problems after the third dose, requiring surgery; another describes myocardial involvement after multiple doses and subsequent inflammatory sequelae. - DNA contamination and analytical findings - Kevin McKernan’s analysis of certain Japanese CoronaVac vaccines is cited: both DNA contamination and the presence of SV40 promoter elements were detected in some vaccine lots, with DNA amounts exceeding some regulatory benchmarks in at least one case. The concern is that DNA contamination, or the presence of promoter sequences, could influence integration or expression in unintended ways. - It is noted that vaccines using lipid nanoparticles can potentially deliver nucleic acids into cells; in the presence of exons or promoter sequences, there could be unintended cellular uptake and expression. - Implications for public health and policy - The panel underscores the need for caution, thorough investigation, and long-term observation of any replication-based vaccine platform before broad deployment. There is a call to evaluate risks, monitor long-term outcomes, and consider the possibility that replication-competent constructs could drive unforeseen evolutionary dynamics within hosts or communities. - There is contention about how information is communicated to the public, with particular emphasis on avoiding misinformation while ensuring that scientific uncertainties are transparently discussed. - Broader scientific context and forward-looking stance - The speakers discuss how the field’s approach to gene-based vaccines is evolving rapidly, and they stress that the compatibility of replicon systems with human biology is not yet fully understood. - They frame their discussion as not merely about current vaccines but about the trajectory of vaccine platforms: if replication-based or self-dispersing systems prove too risky or unpredictable, the prudent path might be to favor conventional, non-replicating strategies until safety, efficacy, and containment of unintended spread are more firmly established. Closing and takeaways - The session closes with emphasis on careful evaluation of replicon vaccines, awareness that viral genetics can behave differently in humans than in theory, and a call for continued discussion, independent verification, and transparent communication as the technology develops. - Throughout, speakers acknowledge the complexity of immune responses to vaccines, the potential for unexpected adverse events, and the importance of safeguarding public health while advancing vaccine science.

Pfizer and Moderna vaccines use two processes. The first process involves using PCR to amplify and create DNA for clinical trials. Once approved, they use circular bacterial DNA plasmid to replicate billions of mRNA DNA sample copies. However, this resulted in contaminated vaccines with junk DNA. A study found DNA fragments in Pfizer and Moderna vaccines in Ontario, Canada. Researchers tested 27 mRNA vials from 12 different lots and discovered billions to 100 billions of DNA molecules per dose, exceeding FDA and WHO guidelines by 188 to 509 times. This is a significant amount, far beyond what is acceptable.

The Pfizer vaccine may contain DNA in addition to mRNA, according to a researcher who sequenced the vaccine in their lab. The DNA is a vector used in the production of the mRNA. The researcher expressed concern about the potential consequences of this, including rare but serious side effects like death from cardiac arrest. The DNA could integrate into the genomic DNA of cells and become a permanent part of them, posing a risk of genome modification and autoimmune attacks. There is also a theoretical risk of future cancer depending on where the foreign DNA lands in the genome. The researcher believes further investigation is needed to determine if these risks are occurring.

The Pfizer vaccine contains DNA contamination in addition to mRNA. The DNA comes from the DNA vector used as a template for making the mRNA. Sequencing analysis of the vaccine revealed the presence of DNA, which could potentially cause serious side effects and integrate into the genomic DNA of cells. This poses risks such as autoimmune attacks and potential future cancer. The DNA contamination likely occurred during the production process. It is important to investigate if this DNA has integrated into the genomes of vaccinated individuals. The FDA should require Pfizer to remove the DNA from future versions of the vaccine. The regulatory limit for DNA in vaccines is outdated and not suitable for this type of vaccine. It is necessary to address this oversight and ensure the safety of the vaccine.

Tokyo Institute of Technology Professor Emeritus Mr. Murakami and I would like to share some information. In March, it was discovered that there is a significant amount of DM mixed in with the RNA, which was supposed to only contain RNA. Multiple researchers have confirmed this. One issue is that some LANWELISH, specifically SV4, promoter sequences are mixed in with the virus genes, which are necessary for gene expression. This can activate the immune system and cause various problems. DNA can induce mutations and easily enter cells, potentially disrupting important genes. The presence of LANWELISH promoter sequences in the virus can increase the risk of cancer. Vaccines that suppress the immune system can further increase the risk of cancer. It is important to minimize impurities in DNA, as they can cause inflammation and immune reactions. Different batches of vaccines may contain different impurities, such as DNA. DNA should not be introduced into cells.